Vanda Pharmaceuticals Inc

자세한 내용은 Vanda Pharmaceuticals Inc 회사

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

회사 정보

종목 코드 VNDA

회사 이름Vanda Pharmaceuticals Inc

상장일Apr 12, 2006

CEODr. Mihael Hristos Polymeropoulos, M.D.

직원 수368

유형Ordinary Share

회계 연도 종료Apr 12

주소Suite 300E

도시WASHINGTON

증권 거래소NASDAQ Global Market Consolidated

국가United States of America

우편 번호20037

전화12027343400

웹사이트https://www.vandapharma.com/

종목 코드 VNDA

상장일Apr 12, 2006

CEODr. Mihael Hristos Polymeropoulos, M.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.33M

+1.31%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

Dr. Stephen Ray Mitchell, M.D.

Independent Director

97.08K

+116.43%

Mr. Timothy I. Williams

Senior Vice President, General Counsel, Secretary

--

Ms. Phaedra S. Chrousos

Independent Director

--

Mr. Joakim (Kim) Wijkstrom

Senior Vice President, Chief Marketing Officer

--

이름

이름/직위

직위

주식 보유

변동

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.33M

+1.31%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Fanapt

23.55M

47.05%

Hetlioz

20.87M

41.71%

PONVORY

5.62M

11.24%

데이터 없음

사업별

지역별

사업별USD

이름

수익

비율

Fanapt

23.55M

47.05%

Hetlioz

20.87M

41.71%

PONVORY

5.62M

11.24%

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

10.18%

Renaissance Technologies LLC

6.04%

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

5.28%

Dimensional Fund Advisors, L.P.

4.30%

Other

68.29%

주주

비율

BlackRock Institutional Trust Company, N.A.

10.18%

Renaissance Technologies LLC

6.04%

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

5.28%

Dimensional Fund Advisors, L.P.

4.30%

Other

68.29%

주주 유형

주주

비율

Investment Advisor

28.86%

Investment Advisor/Hedge Fund

26.88%

Hedge Fund

19.28%

Individual Investor

7.20%

Research Firm

2.93%

Pension Fund

0.44%

Bank and Trust

0.20%

Sovereign Wealth Fund

0.20%

Venture Capital

0.12%

Other

13.90%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

415

50.78M

86.17%

-11.31M

2025Q1

426

48.51M

82.37%

-12.27M

2024Q4

444

46.48M

79.71%

-15.23M

2024Q3

446

47.42M

81.36%

-14.93M

2024Q2

445

46.99M

80.73%

-18.42M

2024Q1

434

53.50M

92.97%

-11.41M

2023Q4

445

55.38M

96.27%

-9.21M

2023Q3

446

56.79M

98.75%

-12.15M

2023Q2

434

60.42M

105.19%

-10.16M

2023Q1

437

62.04M

109.27%

-2.85M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

6.02M

10.21%

+16.86K

+0.28%

Mar 31, 2025

Renaissance Technologies LLC

3.57M

6.05%

-287.37K

-7.46%

Mar 31, 2025

The Vanguard Group, Inc.

3.50M

5.93%

-11.00K

-0.31%

Mar 31, 2025

Millennium Management LLC

3.12M

5.29%

+980.75K

+45.84%

Jun 27, 2025

Dimensional Fund Advisors, L.P.

2.54M

4.31%

+51.16K

+2.06%

Mar 31, 2025

Tang Capital Management, LLC

2.35M

3.99%

--

Mar 31, 2025

Polymeropoulos (Mihael Hristos)

2.33M

3.95%

+30.00K

+1.31%

May 21, 2025

BlackRock Financial Management, Inc.

2.15M

3.64%

+14.97K

+0.70%

Mar 31, 2025

Acadian Asset Management LLC

1.89M

3.2%

-12.95K

-0.68%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.61M

2.74%

+163.33K

+11.26%

Mar 31, 2025

4.175USD

Vanda Pharmaceuticals Inc

4.175

개요

회사

금융